HC Wainwright Has Positive Opinion of LXRX FY2026 Earnings

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) – Research analysts at HC Wainwright raised their FY2026 earnings per share estimates for shares of Lexicon Pharmaceuticals in a research note issued to investors on Thursday, November 5th. HC Wainwright analyst J. Pantginis now anticipates that the biopharmaceutical company will post earnings per share of ($0.14) for the year, up from their previous estimate of ($0.15). The consensus estimate for Lexicon Pharmaceuticals’ current full-year earnings is ($0.16) per share. HC Wainwright also issued estimates for Lexicon Pharmaceuticals’ FY2027 earnings at ($0.19) EPS, FY2028 earnings at ($0.16) EPS, FY2029 earnings at ($0.17) EPS and FY2030 earnings at ($0.09) EPS.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last released its quarterly earnings results on Thursday, November 5th. The biopharmaceutical company reported ($0.03) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.06) by $0.03. Lexicon Pharmaceuticals had a negative return on equity of 35.76% and a negative net margin of 161.80%. The business had revenue of $11.25 million during the quarter, compared to the consensus estimate of $4.14 million.

LXRX has been the subject of a number of other research reports. Cantor Fitzgerald started coverage on Lexicon Pharmaceuticals in a report on Monday, September 28th. They set an “overweight” rating and a $8.00 target price for the company. Weiss Ratings restated a “sell (d-)” rating on shares of Lexicon Pharmaceuticals in a research note on Wednesday, October 21st. Citigroup upped their price target on shares of Lexicon Pharmaceuticals from $3.10 to $3.40 and gave the company a “buy” rating in a research note on Monday. Wall Street Zen raised shares of Lexicon Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Sunday. Finally, Zacks Research lowered shares of Lexicon Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Monday, August 3rd. Three equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $5.80.

Lexicon Pharmaceuticals Stock Performance

LXRX stock opened at $1.86 on Monday. The company has a current ratio of 10.62, a quick ratio of 10.56 and a debt-to-equity ratio of 0.32. The business’s fifty day moving average price is $1.80 and its two-hundred day moving average price is $1.89. Lexicon Pharmaceuticals has a fifty-two week low of $1.10 and a fifty-two week high of $2.68.

Insiders Place Their Bets

In other Lexicon Pharmaceuticals news, CEO Michael Exton bought 30,064 shares of the firm’s stock in a transaction on Friday, November 6th. The shares were purchased at an average price of $1.66 per share, for a total transaction of $49,906.24. Following the completion of the transaction, the chief executive officer directly owned 328,496 shares in the company, valued at approximately $545,303.36. The trade was a 10.07% increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link. 14.00% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in LXRX. Siren L.L.C. grew its holdings in shares of Lexicon Pharmaceuticals by 13.8% during the 1st quarter. Siren L.L.C. now owns 44,303,518 shares of the biopharmaceutical company’s stock valued at $69,113,000 after purchasing an additional 5,384,615 shares during the last quarter. Renaissance Technologies LLC increased its position in Lexicon Pharmaceuticals by 508.0% during the 1st quarter. Renaissance Technologies LLC now owns 1,600,500 shares of the biopharmaceutical company’s stock worth $2,497,000 after purchasing an additional 1,337,246 shares in the last quarter. Bank of New York Mellon Corp acquired a new position in Lexicon Pharmaceuticals during the 2nd quarter worth approximately $1,365,000. Bank of America Corp DE lifted its stake in Lexicon Pharmaceuticals by 415.3% in the 1st quarter. Bank of America Corp DE now owns 526,103 shares of the biopharmaceutical company’s stock valued at $821,000 after purchasing an additional 424,006 shares during the last quarter. Finally, ADAR1 Capital Management LLC bought a new position in Lexicon Pharmaceuticals in the 1st quarter valued at approximately $1,170,000. Institutional investors own 74.70% of the company’s stock.

Trending Headlines about Lexicon Pharmaceuticals

Here are the key news stories impacting Lexicon Pharmaceuticals this week:

• Positive Sentiment: CEO Michael Exton bought 30,064 shares at an average $1.66, increasing his stake by about 10%. Insider purchases can signal confidence in the company’s prospects. Insider purchase report
• Positive Sentiment: Citigroup raised its price target from $3.10 to $3.40 and maintained a Buy rating, a more optimistic analyst view that may support investor sentiment. Citigroup ratings
• Positive Sentiment: New investigator-led research reported that sotagliflozin reduced thrombus formation in a crossover study and acutely lowered myocardial work in living heart tissue from patients with hypertrophic cardiomyopathy. These findings provide mechanistic evidence for the drug, but do not establish clinical benefit; SONATA-HCM topline results are expected in Q1 2027. Lexicon research announcement
• Neutral Sentiment: A report says short interest totaled zero shares as of November 10, despite describing this as an increase. The conflicting wording makes the figure difficult to interpret as a clear trading signal.
• Neutral Sentiment: Recent analyst views remain mixed: the report cites three Buy ratings, one Hold and one Sell, with an overall consensus Hold. Analyst insights

About Lexicon Pharmaceuticals

Lexicon Pharmaceuticals is a biopharmaceutical company based in The Woodlands, Texas. Founded in 1995 as Lexicon Genetics, the company uses drug discovery and development research to create medicines for serious diseases, with a focus on areas of unmet medical need. Its commercial product, Inpefa (sotagliflozin), is approved in the United States to reduce the risk of cardiovascular death and worsening heart failure in adults with heart failure. Lexicon also develops investigational medicines, including candidates studied for neuropathic pain and other conditions.